DOCSLIB.ORG

The Role of Low-Potency Topical Steroids in Day-To-Day Practice

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Role of Low-Potency Topical Steroids in Day-To-Day Practice Supplement to the December 2009 &AGING Series: Relevance of Low-Potency Topical Steroids in Dermatology The Role of Low-Potency Topical Steroids in Day-to-Day Practice Supplement supported by ® HMP COMMUNICATIONS 83 GENERAL WARREN BLVD, SUITE 100, MALVERN, PA 19355 • (800) 237-7285 • (610) 560-0500 • FAX (610) 560-0501 EDITORIAL STAFF DESIGN AND PRODUCTION BUSINESS STAFF EXECUTIVE EDITOR STEFANIE TULEYA CREATIVE DIRECTOR VIC GEANOPULOS VICE PRESIDENT/GROUP PUBLISHER WILLIAM W. HARLEY MANAGING EDITOR ELLEN MEYER ART DIRECTOR KAREN COPESTAKES NATIONAL ACCOUNT MANAGER ROBYN TANZER SPECIAL PROJECTS EDITOR STEPHANIE WASEK PRODUCTION MANAGER TRISH MORRIS 2009-560-018-A The Role of Low-Potency Topical Steroids in Day-to-Day Practice Johnnie M. Woodson, MD Assistant Clinical Professor of Dermatology University of Nevada School of Medicine Henderson, NV opical corticosteroids are one of the oldest treat - matitis, psoriasis, pityriasis rosea, nummular dermatitis, atopic ments for a variety of dermatologic conditions. dermatitis, dyshidrotic eczema, diaper dermatitis, erythro - TThey are used to treat conditions such as psoriasis, derma, lichen simplex chronicus, lichen planus, alopecia vitiligo, eczema, atopic dermatitis, phimosis, acute radia - areata, pruritus, vitiligo, acne keloidalis nuchae and granuloma tion dermatitis and lichen sclerosus. 1 Topical corticos - annulare. Ference and Last note that the keys to successful teroids are also used to treat melasma, chronic idiopathic treatment “[depend] on an accurate diagnosis and consider - urticaria and alopecia areata, but evidence of efficacy ation of the steroid's delivery vehicle, potency, frequency of with these conditions is limited. 1 application, duration of treatment and side effects.” 1 Further, their long history of safety and effectiveness To describe the effect intensity of topical corticos - for certain conditions means they remain one of the most teroids, potency is the term used. To measure the anti-in - useful and widely prescribed treatments in day-to-day flammatory and the antiproliferative properties, certain dermatologic practice — nearly 1.7 million prescriptions assays are utilized. A very commonly used assay is the are dispensed each year for treatment of dermatological vasoconstrictor assay and this is usually used by re - conditions (see Table 1 ). 2 searchers because it correlates well with clinical efficacy. These benefits — safety, use across a wide spectrum of The test is subjective, which is one of the disadvantages dermatoses — make topical corticosteroids a desirable of using this assay. Clinical potency of topical corticos - tool for any dermatologist. This article will specifically teroids usually depends on several factors, including the explore the role and use of topical low-potency steroids structure of the molecule, the area of the skin it is applied (LPS) in day-to-day practice. to and the vehicle it is used in. Topical corticosteroids can have a number of undesir - LPS AS DAILY TREATMENT able side effects, including atrophic changes, more fragile Some of the selected indications of topical corticosteroids skin, more easily bruised skin, increased risk for infection, in dermatologic uses are for the treatment of seborrheic der - masked infection, secondary infection, contact dermatitis, TABLE 1. DERMATOLOGY: LOW-POTENCY TOPICAL STEROID PRESCRIPTIONS OVER 1 YEAR VEHICLE PRESCRIPTIONS FILLED Ointment 413,759 Cream 727,030 Liquid 545,750 Combination form 2,923 TOTAL 1,689,462 Note: Wolters Kluwer data gathered over 12 months in 2008–09. 2 Supplement to Skin & Aging N December 2009 3 LOW-DOSE STEROIDS FIGURE 1. While higher-potency topical steroid formula - FIGURE 2. Successful treatments target the root cause to tions may be used short-term in particularly acute cases, relieve symptoms and improve quality-of-life factors such as avoid them for use longer than 3 weeks and on more sensi - physiological distress and embarrassment with appearance tive areas of the body, such as the face, groin and axilla. of skin and/or constant scratching. delayed wound healing, hyperpigmentation, hypopig - ment before the desired response is achieved, while a se - mentation and photosensitization. 1 vere case may not respond, or may respond very little, Because of this, dermatologists want to use the lowest- even after long-term use. 5 potency steroid that will effectively alleviate symptoms of Strategies in such acute cases include varying the dose dermatoses. 3 While higher-potency formulations may be (e.g., using stronger topical steroids on weekends and used short-term in particularly acute cases, they are to be weaker formulations on weekdays); stepping up the dose avoided for long-term use — longer than 2 weeks — and (i.e., starting weaker and moving to a stronger formula - on more sensitive areas of the body, such as the face, groin tion); or stepping down the dose (ie, starting more potent and axilla. 1,3,4 Milder formulations are therefore used when and gradually moving to a less-potent formulation). 5,6 day-to-day maintenance or topical use on sensitive skin, Trial and error is often necessary in order to tailor the thinner skin or children’s skin is called for. 1,4 dosage and schedule to each patient. 1 This doesn’t mean a dermatologist should use a topical When prescribing, dermatologists need to take into ac - count the following safety considera - tions: body surface area, duration and A formulation that combines hydrocortisone acetate and individual patient needs. Considering these factors is important in order to pramoxine hydrochloride results in the ability to relieve avoid potential side effects. In fact, se - pruritus and inflammation associated with many dermatoses. vere side effects are rare with topical LPS, even when they are used over many years. 4 steroid potency that is too low to treat a given patient’s symptoms. Rather, the idea is to match lowest strength and MECHANISMS OF ACTION smallest quantity of corticosteroid to properly address the Topical corticosteroids have anti-inflammatory and an - severity of the dermatosis the patient has presented with. 5 tiproliferative effects. The immediate anti-inflammatory For example, mild eczema can be treated with twice- effects are that they stabilize cell membranes and prevent a-day topical LPS, often completely clearing the outbreak the release of lysosomal contents; they reduce vascular within 1 or 2 weeks. 1,5 Moderate eczema may require a smooth muscle and sensitivity to histamine; they reduce more potent formulation and/or longer duration of treat - mast cell sensitization induced by immunoglobulin E; and 4 December 2009 N Supplement to Skin & Aging TABLE 2. EXAMPLES OF COMMON CORTICOSTEROID-RESPONSIVE DERMATOSES • Allergic dermatitis • Poison plant eruptions (poisons ivy, oak and sumac) • Atopic dermatitis/eczema • Post-chicken pox • Contact dermatitis • Post-scabies (allergic and irritant-specific) • Pruritus ani • Drug eruptions • Pruritus (specific and non-specific) • Insect bites • Sunburn • Lichen sclerosus/planus/striatus • Urticaria • Neurodermatitis (lichen simplex chronicus) TABLE 3. ONSET OF RELIEF TIME (RELATING TO ITCH-SCRATCH CYCLE) PRODUCT ONSET OF ACTION PEAK EFFECT DURATION OF ACTION Pramoxine hydrochloride 2 to 5 minutes 3 to 5 minutes Several days Hydrocortisone acetate slow n/a long Note: Adapted from University of Maryland Medical Center Complimentary and Alternative Medicine Index. 14,15 they inhibit the release of histamine and other mast cell BENEFITS OF PRAMOXINE mediators. Topical corticosteroids can also decrease the Because of its anesthetic properties, the addition of natural cell-killing activity and decrease response to lym - pramoxine may be helpful in ameliorating itch sensation. 7 phocyte reaction. Pramoxine hydrochloride is widely used as a surface In my experience, topical glucocorticosteroids also anesthetic because it combines effectiveness with low sys - have delayed anti-inflammatory effects, such as preventing temic toxicity. 8 According to a 1954 study by Peal and formation of potent inflammatory mediators, decreasing Karp, it exhibits low potential for sensitization and irri - vascular permeability, and producing the induction of tation. 9 Subsequent study has confirmed the safety profile anti-inflammatory proteins. Glucocorticosteroids act on and wide-ranging effectiveness of pramoxine. different cell types, including polymorphonuclear leuko - A double-blind study of 15 patients examined how the cytes (PMNs) and lymphocytes. They decrease PMN application of pramoxine lotion and pramoxine vehicle movement to inflammation sites, reduce PMN numbers affected perception of histamine-induced pruritus and at inflammation sites, and decrease their ability to attach the warmth and pain thresholds that result from this pru - to the inside of vascular channels called the endothelium. ritus. The authors found that, while cold and heat pain Glucocorticosteroids can also decrease the production of thresholds were unaffected, warmth sensation threshold certain interleukins as well as tumor necrosis factor. increased significantly — by 0.4˚ C — after histamine- I’ve also found that topical glucocorticosteroids exhibit induced itch. 10 Pramoxine lotion was found to signifi - antiproliferative effects that can affect each of the skin’s cantly reduce the cold pain threshold, while pramoxine layers. For example, in the epidermis, they can decrease vehicle significantly decreased warmth sensation; the re - the thickness of the stratum corneum, affect the ker
Load more

Recommended publications
  • A Diagnostic Approach to Pruritus
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by DigitalCommons@University of Nebraska University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln U.S. Air Force Research U.S. Department of Defense 2011 A Diagnostic Approach to Pruritus Brian V. Reamy Christopher W. Bunt Stacy Fletcher Follow this and additional works at: https://digitalcommons.unl.edu/usafresearch This Article is brought to you for free and open access by the U.S. Department of Defense at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in U.S. Air Force Research by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. A Diagnostic Approach to Pruritus BRIAN V. REAMY, MD, Uniformed Services University of the Health Sciences, Bethesda, Maryland CHRISTOPHER W. BUNT, MAJ, USAF, MC, and STACY FLETCHER, CAPT, USAF, MC Ehrling Bergquist Family Medicine Residency Program, Offutt Air Force Base, Nebraska, and the University of Nebraska Medical Center, Omaha, Nebraska Pruritus can be a symptom of a distinct dermatologic condition or of an occult underlying systemic disease. Of the patients referred to a dermatologist for generalized pruritus with no apparent primary cutaneous cause, 14 to 24 percent have a systemic etiology. In the absence of a primary skin lesion, the review of systems should include evaluation for thyroid disorders, lymphoma, kidney and liver diseases, and diabetes mellitus. Findings suggestive of less seri- ous etiologies include younger age, localized symptoms, acute onset, involvement limited to exposed areas, and a clear association with a sick contact or recent travel. Chronic or general- ized pruritus, older age, and abnormal physical findings should increase concern for underly- ing systemic conditions.
    [Show full text]
  • FIG. 4A © O O Wo 2015/042110 Al III III II II III III 1 1 II III II II III III II III
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2015/042110 A l 2 6 March 2015 (26.03.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61P 37/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US20 14/056021 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, ΓΝ , IR, IS, JP, KE, KG, KN, KP, KR, 17 September 2014 (17.09.2014) KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (25) Filing Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/880,522 20 September 2013 (20.09.2013) (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: CHILDREN'S MEDICAL CENTER COR¬ GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, PORATION [US/US]; 55 Shattuck Street, Boston, Mas¬ TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, sachusetts 021 15 (US).
    [Show full text]
  • ORIGINAL ARTICLE a Clinical and Histopathological Study of Lichenoid Eruption of Skin in Two Tertiary Care Hospitals of Dhaka
    ORIGINAL ARTICLE A Clinical and Histopathological study of Lichenoid Eruption of Skin in Two Tertiary Care Hospitals of Dhaka. Khaled A1, Banu SG 2, Kamal M 3, Manzoor J 4, Nasir TA 5 Introduction studies from other countries. Skin diseases manifested by lichenoid eruption, With this background, this present study was is common in our country. Patients usually undertaken to know the clinical and attend the skin disease clinic in advanced stage histopathological pattern of lichenoid eruption, of disease because of improper treatment due to age and sex distribution of the diseases and to difficulties in differentiation of myriads of well assess the clinical diagnostic accuracy by established diseases which present as lichenoid histopathology. eruption. When we call a clinical eruption lichenoid, we Materials and Method usually mean it resembles lichen planus1, the A total of 134 cases were included in this study prototype of this group of disease. The term and these cases were collected from lichenoid used clinically to describe a flat Bangabandhu Sheikh Mujib Medical University topped, shiny papular eruption resembling 2 (Jan 2003 to Feb 2005) and Apollo Hospitals lichen planus. Histopathologically these Dhaka (Oct 2006 to May 2008), both of these are diseases show lichenoid tissue reaction. The large tertiary care hospitals in Dhaka. Biopsy lichenoid tissue reaction is characterized by specimen from patients of all age group having epidermal basal cell damage that is intimately lichenoid eruption was included in this study. associated with massive infiltration of T cells in 3 Detailed clinical history including age, sex, upper dermis. distribution of lesions, presence of itching, The spectrum of clinical diseases related to exacerbating factors, drug history, family history lichenoid tissue reaction is wider and usually and any systemic manifestation were noted.
    [Show full text]
  • Triamcinolone Acetonide Cream USP, 0.025%, 0.1%, 0.5% for Dermatologic Use Only Not for Ophthalmic Use Rx Only
    TRIAMCINOLONE ACETONIDE- triamcinolone acetonide cream Padagis Israel Pharmaceuticals Ltd ---------- Triamcinolone Acetonide Cream USP, 0.025%, 0.1%, 0.5% For Dermatologic Use Only Not For Ophthalmic Use Rx Only DESCRIPTION The topical corticosteroids constitute a class of primarily synthetic steroids used as anti- inflammatory and anti-pruritic agents. Triamcinolone acetonide is designated chemically as pregna-1,4-diene-3,20-dione,9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene) bis (oxy)]-,(11ß,16α)-. C24H31FO6, and M.W. of 434.51; CAS Reg. No. 76-25-5. Each gram of 0.025%, 0.1% and 0.5% Triamcinolone Acetonide Cream USP contains 0.25 mg, 1 mg, or 5 mg triamcinolone acetonide respectively, in a washable cream base of cetyl alcohol, cetyl esters wax, glycerin, glyceryl monostearate, isopropyl palmitate, polysorbate-60, propylene glycol, purified water, sorbic acid, and sorbitan monostearate. CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics - The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids.
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Audaval 0.1% Ointment 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One gram of ointment contains 1 mg of betamethasone (0.1% w/w) as valerate. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Ointment Opaque ointment. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications Audaval preparations are indicated for the treatment of: eczema in children over 1 year elderly and adults; including atopic and discoid eczemas; prurigo nodularis; psoriasis (excluding widespread plaque psoriasis); neurodermatoses, including lichen simplex, lichen planus; seborrhoeic dermatitis; contact sensitivity reactions; discoid lupus erythematosus and they may be used as an adjunct to systemic steroid therapy in generalised erythroderma. In general, ointment preparations are particularly appropriate for dry, lichenified or scaly skin conditions whereas a cream preparation may be more suitable in the case of moist or weeping lesions. 4.2 Posology and method of administration For topical use only. If no improvement is seen after two to four weeks, the diagnosis should be reconsidered and specialist referral may be necessary. Adults, adolescents and the elderly A small quantity of Audaval should be applied to the affected area one to three times daily as directed by physician until improvement occurs. It may then be possible to maintain improvement by applying once a day, or even less often, or by using the appropriate ready diluted (1 in 4) preparation, Audaval RD 0.025% Ointment. Allow adequate time for absorption after each application before applying an emollient. If no improvement is seen within two to four weeks, reassessment of the diagnosis, or referral, may be necessary.
    [Show full text]
  • Common Dermatoses in Patients with Obsessive Compulsive Disorders Mircea Tampa Carol Davila University of Medicine and Pharmacy, Tampa [email protected]
    Journal of Mind and Medical Sciences Volume 2 | Issue 2 Article 7 2015 Common Dermatoses in Patients with Obsessive Compulsive Disorders Mircea Tampa Carol Davila University of Medicine and Pharmacy, [email protected] Maria Isabela Sarbu Victor Babes Hospital for Infectious and Tropical Diseases, [email protected] Clara Matei Carol Davila University of Medicine and Pharmacy Vasile Benea Victor Babes Hospital for Infectious and Tropical Diseases Simona Roxana Georgescu Carol Davila University of Medicine and Pharmacy Follow this and additional works at: http://scholar.valpo.edu/jmms Part of the Medicine and Health Sciences Commons Recommended Citation Tampa, Mircea; Sarbu, Maria Isabela; Matei, Clara; Benea, Vasile; and Georgescu, Simona Roxana (2015) "Common Dermatoses in Patients with Obsessive Compulsive Disorders," Journal of Mind and Medical Sciences: Vol. 2 : Iss. 2 , Article 7. Available at: http://scholar.valpo.edu/jmms/vol2/iss2/7 This Review Article is brought to you for free and open access by ValpoScholar. It has been accepted for inclusion in Journal of Mind and Medical Sciences by an authorized administrator of ValpoScholar. For more information, please contact a ValpoScholar staff member at [email protected]. JMMS 2015, 2(2): 150- 158. Review Common dermatoses in patients with obsessive compulsive disorders Mircea Tampa1, Maria Isabela Sarbu2, Clara Matei1, Vasile Benea2, Simona Roxana Georgescu1 1 Carol Davila University of Medicine and Pharmacy, Department of Dermatology and Venereology 2 Victor Babes Hospital for Infectious and Tropical Diseases, Department of Dermatology and Venereology Corresponding author: Maria Isabela Sarbu, e-mail: [email protected] Running title: Dermatoses in obsessive compulsive disorders Keywords: Factitious disorders, obsessive-compulsive disorders, acne excoriee www.jmms.ro 2015, Vol.
    [Show full text]
  • Lichen Simplex Chronicus
    LICHEN SIMPLEX CHRONICUS http://www.aocd.org Lichen simplex chronicus is a localized form of lichenified (thickened, inflamed) atopic dermatitis or eczema that occurs in well defined plaques. It is the result of ongoing, chronic rubbing and scratching of the skin in localized areas. It is generally seen in patients greater than 20 years of age and is more frequent in women. Emotional stress can play a part in the course of this skin disease. There is mainly one symptom: itching. The rubbing and scratching that occurs in response to the itch can become automatic and even unconscious making it very difficult to treat. It can be magnified by seeming innocuous stimuli such as putting on clothes, or clothes rubbing the skin which makes the skin warmer resulting in increased itch sensation. The lesions themselves are generally very well defined areas of thickened, erythematous, raised area of skin. Frequently they are linear, oval or round in shape. Sites of predilection include the back of the neck, ankles, lower legs, upper thighs, forearms and the genital areas. They can be single lesions or multiple. This can be a very difficult condition to treat much less resolve. It is of utmost importance that the scratching and rubbing of the skin must stop. Treatment is usually initiated with topical corticosteroids for larger areas and intralesional steroids might also be considered for small lesion(s). If the patient simply cannot keep from rubbing the area an occlusive dressing might be considered to keep the skin protected from probing fingers. Since this is not a histamine driven itch phenomena oral antihistamines are generally of little use in these cases.
    [Show full text]
  • St John's Institute of Dermatology
    St John’s Institute of Dermatology Topical steroids This leaflet explains more about topical steroids and how they are used to treat a variety of skin conditions. If you have any questions or concerns, please speak to a doctor or nurse caring for you. What are topical corticosteroids and how do they work? Topical corticosteroids are steroids that are applied onto the skin and are used to treat a variety of skin conditions. The type of steroid found in these medicines is similar to those produced naturally in the body and they work by reducing inflammation within the skin, making it less red and itchy. What are the different strengths of topical corticosteroids? Topical steroids come in a number of different strengths. It is therefore very important that you follow the advice of your doctor or specialist nurse and apply the correct strength of steroid to a given area of the body. The strengths of the most commonly prescribed topical steroids in the UK are listed in the table below. Table 1 - strengths of commonly prescribed topical steroids Strength Chemical name Common trade names Mild Hydrocortisone 0.5%, 1.0%, 2.5% Hydrocortisone Dioderm®, Efcortelan®, Mildison® Moderate Betamethasone valerate 0.025% Betnovate-RD® Clobetasone butyrate 0.05% Eumovate®, Clobavate® Fluocinolone acetonide 0.001% Synalar 1 in 4 dilution® Fluocortolone 0.25% Ultralanum Plain® Fludroxycortide 0.0125% Haelan® Tape Strong Betamethasone valerate 0.1% Betnovate® Diflucortolone valerate 0.1% Nerisone® Fluocinolone acetonide 0.025% Synalar® Fluticasone propionate 0.05% Cutivate® Hydrocortisone butyrate 0.1% Locoid® Mometasone furoate 0.1% Elocon® Very strong Clobetasol propionate 0.1% Dermovate®, Clarelux® Diflucortolone valerate 0.3% Nerisone Forte® 1 of 5 In adults, stronger steroids are generally used on the body and mild or moderate steroids are used on the face and skin folds (armpits, breast folds, groin and genitals).
    [Show full text]
  • Clobetasol Propionate Lotion in the Treatment of Moderate to Severe Plaque-Type Psoriasis
    THERAPEUTICS FOR THE CLINICIAN Clobetasol Propionate Lotion in the Treatment of Moderate to Severe Plaque-Type Psoriasis Jacques Decroix, MD; Henrik Pres, MD; Nicolaï Tsankov, MD; Michel Poncet, PhD; Stéphanie Arsonnaud Owing to its anti-inflammatory, antipruritic, soriasis is a lifelong condition, with onset vasoconstrictive, and immune-modulating prop- occurring at any time throughout life. It erties, clobetasol propionate is used to treat P affects men and women equally, and almost all psoriasis. This study was conducted to evaluate races in varying rates of frequency are affected. Pso- the efficacy, safety, and cosmetic acceptability riasis usually first appears between the ages of 15 of clobetasol propionate lotion compared with and 30 years and may occur anywhere on the body. its vehicle and with clobetasol propionate Psoriasis is an inherited condition; however, cream in the treatment of moderate to severe both genetic and environmental factors play an plaque-type psoriasis. important role in its onset and course. The condi- A total of 222 patients were treated. After tion has a considerable impact on quality of life, 4 weeks of treatment, clobetasol propionate with patients complaining about the messiness of lotion was more efficient than vehicle lotion and the topical agents used to treat the condition and of equivalent efficacy as clobetasol propionate the profound psychological impact of the treat- cream. Cosmetic acceptability was significantly ments and the condition.1-5 better with clobetasol propionate lotion than with Clobetasol propionate is known for its anti- clobetasol propionate cream. Clobetasol propi- inflammatory, antipruritic, vasoconstrictive, and onate lotion was efficient, safe, and well toler- immune-modulating properties and is currently ated and offers a significantly higher cosmetic used in the treatment of certain hyperproliferative advantage in the treatment of moderate to or inflammatory dermatoses, including psoriasis severe plaque-type psoriasis compared with and atopic dermatitis.
    [Show full text]
  • Triamcinolone Acetonide Injectable Suspension, USP)
    KENALOG®-10 INJECTION (triamcinolone acetonide injectable suspension, USP) NOT FOR USE IN NEONATES CONTAINS BENZYL ALCOHOL For Intra-articular or Intralesional Use Only NOT FOR INTRAVENOUS, INTRAMUSCULAR, INTRAOCULAR, EPIDURAL, OR INTRATHECAL USE DESCRIPTION Kenalog®-10 Injection (triamcinolone acetonide injectable suspension, USP) is triamcinolone acetonide, a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intralesional and intra-articular injection. THIS FORMULATION IS SUITABLE FOR INTRA-ARTICULAR AND INTRALESIONAL USE ONLY. Each mL of the sterile aqueous suspension provides 10 mg triamcinolone acetonide, with 0.66% sodium chloride for isotonicity, 0.99% (w/v) benzyl alcohol as a preservative, 0.63% carboxymethylcellulose sodium, and 0.04% polysorbate 80. Sodium hydroxide or hydrochloric acid may have been added to adjust pH between 5.0 and 7.5. At the time of manufacture, the air in the container is replaced by nitrogen. The chemical name for triamcinolone acetonide is 9-Fluoro-11β,16α,17,21-tetrahydroxypregna- 1,4-diene-3,20-dione cyclic 16,17-acetal with acetone. Its structural formula is: 1 Reference ID: 4241593 MW 434.50 CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt- retaining properties, are used as replacement therapy in adrenocortical deficiency states.
    [Show full text]
  • Seborrheic Dermatitis
    432 Teams Dermatology Done by: Wael Al Saleh & Abdulrahman Al-Akeel Reviewer: Wael Al Saleh & Abdulrahman Al-Akeel 9 Team Leader: Basil Al Suwaine Color Code: Original, Team’s note, Important, Doctor’s note, Not important, Old teamwork 432 Dermatology Team Lecture 9: Atopic dermatitis/ Eczema Objectives 1- To know the definition & classification of Dermatitis/Eczema 2- To recognize the primary presentation of different types of eczema 3- To understand the possible pathogenesis of each type of eczema 4- To know the scheme of managements lines P a g e | 1 432 Dermatology Team Lecture 9: Atopic dermatitis/ Eczema Introduction: A groups and spectrum of related disorders with pruritus being the hallmark of the disease, they also come with dry skin. Every atopic dermatitis is eczema but not every eczema are atopic dermatitis. Atopic dermatitis mean that the patient has eczema (excoriated skin, itching and re-onset) and atopy (atopy; the patient or one of his family has allergic rhinitis, asthma or eczema). It starts early of life (eczema can happen at any time). It classified as: - Acute, characterized by erythema, papules, vesicles, oozing, and crusting. - Subacute, clinically it is represented by erythema, scaling, and crusting. - Chronic, presents with thickening of the skin, skin markings become prominent (lichenification); pigmentation and fissuring of the skin occur. Acute on top of chronic very dry 4 years old boy with chronic, itchy, well defined brownish plaque with bleeding plaques. lichenifications. Ill defined plaques Well defined erythematous excoriated Lichenification is the hallmark for plaques on both cheeks with erosion. chronic course. P a g e | 2 432 Dermatology Team Lecture 9: Atopic dermatitis/ Eczema Dermatitis Classification of dermatitis: Atopic, more common in children Seborrheic (oily skin)- (like naso-labial folds, scalp, ears) Contact dermatitis, substance cause eczema - Allergic - Irritant Nummular, coined shape, usually in the shin.
    [Show full text]
  • Xerotic Eczema
    433 Dermatology Team Other type of eczema Lecture(10) Other type of eczema [email protected] 1 | P a g e 433 Dermatology Team Other type of eczema Content of lecture: To know the classification of Eczema. To recognize the primary presentation of different types of eczema. To understand the possible pathogenesis of each type of eczema. To know the scheme of managements lines. Color index: slides, doctor notes, 432 notes, Important 2 | P a g e 433 Dermatology Team Other type of eczema 1-Nummular Dermatitis: Coin shaped patches and plaques Secondary to xerosis cutis Primary symptom itch Notice the surrounding xerosis 2- Regional Eczema: A. Ear eczema B. Eyelid dermatitis Note: using of moisturizing C. Nipple eczema woreworse perorbital D. Hand eczema dermatitis. E. Diaper dermatitis F. Juvenile plantar dermatosis A- Ear Eczema Most frequently caused by seborrheic or atopic dermatitis Staph, Strep, or Psoeudomonas Earlobe is pathognomonic of nickel allergy B- Eyelid dermatitis When on one eye only, it is most frequently caused by nail polish When both eyelids are involved, consider mascara, eye shadow, eyelash cement, eyeliner, etc 3 | P a g e 433 Dermatology Team Other type of eczema C- Nipple eczema Painful fissuring, seen especially in nursing mothers. Maybe an isolated manifestation of atopic dermatitis. If persist more than 3 month, and/or unilateral, biopsy is mandatory to rule out Pagets disease . D- Hand eczema Spongiosis histologically . Irritant hand dermatitis- seen in homemakers, nurses. Resulting from excessive exposure to soaps. Pompholyx- tapioca vesicles, on sides of fingers, palms, and soles. Irritant versus allergic. Note: Adult atopic dermatitis has the greatest risk for hand dermatitis E- Juvenile plantar dermatitis Begins as a patchy symmetrical, smooth, red, glazed macules on the base of the great toes Affect age 3 to puberty.
    [Show full text]